The first step was to separate the tumor samples into two groups by the high and low expression of LAMP3, and then we calculated the StromalScore, ImmuneScore and ESTIMATEScore for each tumor sample, finding that all three scores were better in the LAMP3 high expression group compared to the LAMP3 low expression group (Figure 6A–6C). This evidence concerns the gene LAMP3 and neoplasm.